AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of fatumumab 20mg SC Monthly in Treatment Naive, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.
Type of Study
Brain Imaging Center (BIC)
University of Colorado Hospital
Anna Shah, MD
Protocol Number: 21-4783
More information available at ClinicalTrials.gov: NCT05084638
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers